Bionano Genomics (MEX:BNGO) Tariff Resilience Score: 4/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BNGO Bionano Genomics Inc MEX:BNGO
61 GF Score
Price MXN20.09
GF Value MXN26.44
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bionano Genomics Tariff Resilience Score?

Bionano Genomics MEX:BNGO 61 Tariff Resilience Score is 4 as of Jul. 20, 2026. GuruFocus rates MEX:BNGO with a GF Score™ of 61/100 and a GF Value™ of MXN26.44 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 833 Medical Devices & Instruments companies, Bionano Genomics ranks better than 70.11% on this metric.

Bionano Genomics has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Bionano Genomics has Bionano Genomics relies on global supply chains for manufacturing and sales. Tariffs on biotech components could impact costs. The company has limited pricing power and faces challenges in quickly switching suppliers, making it moderately vulnerable to tariffs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bionano Genomics might have Average Resilient.

Bionano Genomics  (MEX:BNGO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bionano Genomics Tariff Resilience Score Related Terms

MEX:BNGO vs UEEC, CUPR, FEMY: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionano Genomics Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Tariff Resilience Score falls into.


MEX:BNGO
61GF Score
Bionano Genomics Inc MEX:BNGO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Bionano Genomics (MEX:BNGO) has a Tariff Resilience Score of 4 as of Jul. 20, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Bionano Genomics ranks #249 out of 833 companies in the Medical Devices & Instruments industry, placing it in the top 29.9%.
Is Bionano Genomics' Tariff Resilience Score too high?
Bionano Genomics' current Tariff Resilience Score is 4. Based on the distribution chart, Bionano Genomics ranks #249 out of 833 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bionano Genomics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Tariff Resilience Score compare to UEEC and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #249 out of 833 companies for Tariff Resilience Score. This puts Bionano Genomics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Bionano Genomics's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN26.44, compared to a current price of MXN20.09 — trading 24% below its estimated fair value. The current Tariff Resilience Score is 4. Bionano Genomics' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Tariff Resilience Score is 4 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?

Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued. The current stock price of MXN20.09 is trading 24% below its estimated GF Value™ of MXN26.44. GuruFocus considers Bionano Genomics to be Modestly Undervalued.

Key valuation signals for MEX:BNGO:

  • Tariff Resilience Score: 4
  • GF Value™: MXN26.44 vs. price of MXN20.09 (24% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionano Genomics Business Description

Other Exchanges BNGO:USA
Address 9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
61GF Score

Get the complete analysis for MEX:BNGO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN20.09
Price
MXN26.44
GF Value